September 2023: Special Issue Volume 8, Issue 2
Drug Pricing in the United States: Theory and Evidence
Special Issue Editors: Mark V. Pauly, Wharton-UPenn, William S. Comanor, UCLA, and H.E. Frech, III, UCSB
Efficiency, Consumer Welfare, and Market Equilibrium in Private Insurance Coverage of Patented Drugs
H.E. Frech, III, UCSB, Mark V. Pauly, Wharton-UPenn, William S. Comanor, UCLA, and Joseph Martinez, Wharton and Perelman School of Medicine, U-Penn
Drug Pricing Decisions and Insurance Coverage: Evidence from Medicare Part D
Benedic N. Ippolito, American Enterprise Institute, and Joseph F. Levy, Johns Hopkins Bloomberg School of Public Health
Decomposition of Pharmaceutical Manufacturer Discounts into Voluntary and Mandatory Discounts for Glucagon-Like Peptide-1 Receptor Agonists
Inmaculada Hernandez, Nico Gabriel, UCSD; Jingchuan Guo, Univ. of Florida; Aryana Sepassi, UCI; Walid F. Gellad, UPMC; Sean Dickson, West Health Policy Center
A Direct Measure of Medical Innovation on Health Care Spending: A Condition-Specific Approach
Abe Dunn and Lasanthi Fernando, U.S. Department of Commerce, and Eli Liebman, Terry College of Business, University of Georgia
The Global Distribution of New Drug R&D Cost: Does the Rest of the World Free Ride?
Angela Chen, Wharton-UPenn, William S. Comanor, UCLA, H.E. Frech, III, UCSB, and Mark V. Pauly, Wharton-UPenn
Arbitrage Deterrence: A Theory of International Drug Pricing
Stephen Salant, University of Michigan